MedTrace Logo

Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts

NCT00658073 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2011-03-08

No results posted yet for this study

Summary

The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.

Conditions

  • Renal Transplant Rejection

Interventions

PROCEDURE

Kidney transplantation with MSCs infusion

Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

PROCEDURE

kidney transplantation without MSC infusion

kidney transplantation with standard immunosuppressive treatment regime

Sponsors & Collaborators

  • Fuzhou General Hospital

    lead OTHER

Principal Investigators

  • Jianming Tan, M.D and Ph.D · Fuzhou General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2010-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658073 on ClinicalTrials.gov